

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 41170

**Title:** Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?

**Reviewer's code:** 03646970

**Reviewer's country:** United States

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2018-07-31

**Date reviewed:** 2018-08-05

**Review time:** 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

This manuscript is submitted as an editorial Authors discuss the role of various anti diabetic agents in treatment of NAFLD and NASH The manuscript is timely in addressing the topic that it does The quality of the manuscript is good Hypothesis,



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

methods, results, Limitations, strengths and ethical standards do not apply to this study  
Major revisions The Manuscript is submitted as an Editorial - The format does not fit  
the format provided here <https://www.wjgnet.com/bpg/GerInfo/214> There is no  
perspective section. While the authors provide a brief review of available data, an  
overarching perspective reviewing any nuances or future directions is missing. Also  
while data from multiple studies is provided there are no comments regarding  
limitations or strengths of studies. Perhaps the study would better fit 'Mini Review'  
Category Minor revisions Small typo on page 4 "either pioglitazon e (30 mg/d) or  
vitamin E" Sentence on page 4 needs restructuring "The results showed that pioglitazone  
significantly improved steatosis and lobular inflammation compared to placebo, while  
the rate of steatohepatitis resolution was higher in the pioglitazone group."

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 41170

**Title:** Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?

**Reviewer's code:** 03259763

**Reviewer's country:** Germany

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2018-07-31

**Date reviewed:** 2018-08-06

**Review time:** 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

The editorial by Maria Kalogirou and Emmanouil Sinakos is written well, and a topic of interest, which could be recommended for publication after some adjustments: Are any systematic meta-analyses available? This should be discussed in the manuscript,

respectively the lack of such studies. It would be of interest to clearly specify which studies for GLP1-based therapies were randomised and double-blinded. Is any data on long-term outcome of GLP1-based therapies available? Are recommendations from EASL/AASLD for GLP1-based therapies available? This or lack of such recommendations should be discussed in the manuscript. Overall, due to the currently available data, the conclusions seem too strong (page 8) "...ultimately bring the struggle to find an effective antidiabetic agent for patients with NAFLD to an end..." and should be tampered down. Minor: Period after et al. recommended, for example, Armstrong et al (page 5, line 24) Check spelling: „mid-2019“ page 7, line 25

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

### *BPG Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 41170

**Title:** Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?

**Reviewer's code:** 03647931

**Reviewer's country:** Egypt

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2018-07-31

**Date reviewed:** 2018-08-12

**Review time:** 12 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

This editorial entitled, treating NAFLD with anti diabetic drugs: Are GLP-1agonists the end of the struggle? The topic is quite interesting as fatty liver disease is one of the major health problems all over the world and lack of an approved medication. Most of the trials



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

included patients with a biopsy-proven NASH. Therefore, I suggest to change the title into: Treating NASH with anti-diabetic drugs: Are GLP-1 agonists the end of the struggle?

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No